BioIVT Acquires BeCytes Biotechnologies
November 4, 2025
BioIVT has acquired BeCytes Biotechnologies, a Barcelona-based provider of ethically sourced human tissues and primary cell isolation services. The deal expands BioIVT's European footprint and strengthens its capabilities for New Approach Methodologies (NAMs) and ADME research; BeCytes will continue to operate from Barcelona and financial terms were not disclosed.
- Buyers
- BioIVT
- Targets
- BeCytes Biotechnologies
- Industry
- Biotechnology
- Location
- Catalonia, Spain
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
BioIVT Acquires ZenBio
August 21, 2024
Healthcare Services
BioIVT has acquired ZenBio, a Durham-based provider of advanced cell products and biospecimen services, to expand its skin-based expertise, primary cell and exosome isolation capabilities, and blood product offerings for pharmaceutical and cosmetics research. The deal strengthens BioIVT's service portfolio and complements recent integrations to accelerate support for drug discovery and cosmeceutical development; financial terms were not disclosed.
-
BioIVT Acquires Valley Biomedical Products & Services
June 28, 2021
Medical Devices
BioIVT, a provider of research models and value-added research services, has acquired Valley Biomedical Products & Services, an FDA-registered manufacturer of in vitro diagnostics, sera, plasma and reagents based in Winchester, Virginia. The acquisition will expand BioIVT’s capabilities in IVD manufacturing and cell & gene therapy support by combining Valley Biomedical’s reagent and blood-product manufacturing with BioIVT’s donor centers and specimen services; BioIVT will continue operating the Winchester facility and retain its staff.
-
BioIVT Acquires XenoTech from Sekisui Chemical
September 12, 2022
Biotechnology
BioIVT has acquired XenoTech, a Kansas City–based provider of ADME‑Tox in vitro models and contract research services, from Sekisui Chemical. The acquisition expands BioIVT's hepatic product portfolio and ADME/DMPK capabilities to better support biopharma customers' preclinical testing needs. Financial terms were not disclosed.
-
Vertex Pharmaceuticals Acquires ViaCyte for $320M
July 11, 2022
Biotechnology
Vertex Pharmaceuticals agreed to acquire clinical-stage cell therapy company ViaCyte for $320 million in cash. The deal gives Vertex additional stem cell lines, IP and GMP manufacturing capabilities intended to accelerate its VX-880 and other cell replacement therapy programs for type 1 diabetes.
-
BioIVT Acquires PrecisionMed
July 18, 2023
Healthcare Services
BioIVT, a global biospecimen solutions provider, has acquired PrecisionMed, LLC, a Carlsbad-based supplier of high-quality human biospecimens and owner of a large longitudinal cerebrospinal fluid (CSF) repository. The acquisition expands BioIVT's supply network, inventory and capacity for CSF and liquid biopsy products while PrecisionMed will continue to operate from its existing headquarters and collection sites.
-
BioIVT Acquires Tennessee Blood Services
April 4, 2022
Healthcare Services
BioIVT acquired Tennessee Blood Services (TBS), a commercial blood bank and donor center based in Memphis, Tennessee. The acquisition expands BioIVT’s donor network and increases its capacity and control over fresh whole blood, plasma, serum and red blood cell supplies for drug and diagnostic development; financial terms were not disclosed.
Track M&A activity that matters to you
Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.